Updated: BlossomHill and Latigo join flourishing IPO queue with cancer, pain drugs

Jean Cui, BlossomHill Therapeutics CEO July 17, 2026 09:54 AM EDT DealsIPOs Tagris­so-chas­ing Blos­somHill en­ters Nas­daq queue as biotech IPOs flour­ish Kyle LaHucik Biotech Correspondent Last sum­mer, ze­ro biotechs made it on­to the pub­lic mar­kets as the in­dus­try weath­ered a sev­en-month dry spell for ini­tial share sales. This time around … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER